

Gabriela Senti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2443749/publications.pdf>

Version: 2024-02-01

42
papers

3,092
citations

218677

26
h-index

289244

40
g-index

42
all docs

42
docs citations

42
times ranked

3634
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. <i>Swiss Medical Weekly</i> , 2020, 150, w20225.	1.6	367
2	Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17908-17912.	7.1	308
3	Immunity in response to particulate antigen-delivery systems. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 333-355.	13.7	277
4	Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1290-1296.	2.9	236
5	Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1470-1476.	2.9	190
6	Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 997-1002.	2.9	180
7	Inflammasome activation and IL-1 β target IL-1 β for secretion as opposed to surface expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18055-18060.	7.1	166
8	Antigen kinetics determines immune reactivity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5189-5194.	7.1	158
9	Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 128-135.	2.9	148
10	Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients. <i>Journal of Immunotherapy</i> , 2010, 33, 848-858.	2.4	131
11	Intralymphatic Injections as a New Administration Route for Allergen-Specific Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 2009, 150, 59-65.	2.1	98
12	Intralymphatic immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 537-543.	2.3	75
13	Intralymphatic Immunotherapy: Update and Unmet Needs. <i>International Archives of Allergy and Immunology</i> , 2019, 178, 141-149.	2.1	71
14	Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. <i>European Journal of Immunology</i> , 2005, 35, 3591-3598.	2.9	46
15	Epicutaneous Immunotherapy for Aeroallergen and Food Allergy. <i>Current Treatment Options in Allergy</i> , 2014, 1, 68-78.	2.2	42
16	Influence of Phytase, EDTA, and Polyphenols on Zinc Absorption in Adults from Porridges Fortified with Zinc Sulfate or Zinc Oxide. <i>Journal of Nutrition</i> , 2014, 144, 1467-1473.	2.9	42
17	Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 193-203.	2.9	42
18	Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 965-967.e4.	2.9	40

#	ARTICLE	IF	CITATIONS
19	Intralymphatic immunotherapy: Time interval between injections is essential. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 930-931.	2.9	40
20	Intralymphatic immunotherapy. <i>World Allergy Organization Journal</i> , 2015, 8, 9.	3.5	39
21	SCIM: universal single-cell matching with unpaired feature sets. <i>Bioinformatics</i> , 2020, 36, i919-i927.	4.1	37
22	Is The Allergen Really Needed in Allergy Immunotherapy?. <i>Current Treatment Options in Allergy</i> , 2015, 2, 72-82.	2.2	36
23	Novel Delivery Routes for Allergy Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 25-37.	1.9	34
24	Intralymphatic Immunotherapy: From the Rationale to Human Applications. <i>Current Topics in Microbiology and Immunology</i> , 2011, 352, 71-84.	1.1	31
25	New routes for allergen immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1525-1533.	3.3	29
26	Novel Administration Routes for Allergen-Specific Immunotherapy: A Review of Intralymphatic and Epicutaneous Allergen-Specific Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 391-406.	1.9	28
27	Allergen immunotherapy in allergic rhinitis: current use and future trends. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 897-906.	3.0	27
28	Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1059-1067.	3.0	26
29	Comparison of Microneedles and Adhesive-Tape Stripping in Skin Preparation for Epicutaneous Allergen Delivery. <i>International Archives of Allergy and Immunology</i> , 2015, 167, 103-109.	2.1	24
30	Risk Assessment of Hymenoptera Re-Sting Frequency: Implications for Decision-Making in Venom Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 86-92.	2.1	20
31	Immunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of Owners. <i>Viruses</i> , 2020, 12, 288.	3.3	19
32	Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2010, 10, 582-586.	2.3	17
33	Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. <i>Vaccine</i> , 2006, 24, 1389-1394.	3.8	16
34	Evaluation of visual analog scales for the assessment of symptom severity in allergic rhinoconjunctivitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2007, 98, 134-138.	1.0	11
35	A Randomized, Double-Blind, Placebo-Controlled Study to Test the Efficacy of Topical 2-Hydroxypropyl-Beta-Cyclodextrin in the Prophylaxis of Recurrent Herpes Labialis. <i>Dermatology</i> , 2013, 226, 247-252.	2.1	10
36	Immunotherapeutic Targeting of Allergic Disease. <i>Inflammation and Allergy: Drug Targets</i> , 2006, 5, 243-252.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Legal and ethical framework for global health information and biospecimen exchange - an international perspective. BMC Medical Ethics, 2020, 21, 8.	2.4	6
38	A Cutaneous Allergen Neutralisation Test That Correlates with the Duration of Venom Immunotherapy. International Archives of Allergy and Immunology, 2006, 141, 377-383.	2.1	5
39	Nickel sensitisation in mice: A critical appraisal. Journal of Dermatological Science, 2010, 58, 186-192.	1.9	5
40	Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans. Frontiers in Allergy, 2022, 3, 832010.	2.8	5
41	Intralymphatic Vaccination. , 2012, , 205-221.		1
42	Novel Allergen Immunotherapy Routes. Current Treatment Options in Allergy, 2016, 3, 102-112.	2.2	0